Quarterly report pursuant to Section 13 or 15(d)

NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.7.0.1
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 9 Months Ended
Jun. 09, 2017
Jun. 09, 2016
Sep. 15, 2016
Mar. 31, 2017
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Mar. 30, 2016
Common stock shares issued         5,057,247   4,875,871  
Common stock warrants outstanding         5,057,247   4,875,871  
Prepaid expenses         $ 357,807   $ 598,484  
Accounts payable         1,977,522   909,156  
Accrued expenses         654,952   958,101  
Accrued interest         97,350   30,871  
Notes payable         5,416,303   672,970  
Common stock options value outstanding         5,057   4,876  
Estimated fair value warrant issued         641,385 $ 1,198,564    
Goodwill         $ 1,586,796   $ 1,586,796  
Reverse stock split 1:15 Reverse stock split, fractional shares issuable to stockholders were rounded up to the nearest whole share, resulting in a reverse split slightly less than 1-for-15 in the aggregate. Reverse stock split of our common stock by a ratio of not less than 1-for-8 and not more than 1-for-20 at any time prior to September 15, 2017.          
Common stock, par value $ 0.001       $ 0.001   $ 0.001  
Leonard-Meron Biosciences [Member]                
Common stock shares issued               1,942,456
Issued and outstanding common stock               41.00%
Common stock warrants outstanding               243,020
Common stock options outstanding               77,252
Tangible assets consisting of cash       $ 255,748        
Prepaid expenses       20,544        
Property and equipment       5,085        
Deposits       2,167        
Intangible assets       19,400,000        
Accounts payable       244,776        
Accrued expenses       598,659        
Accrued compensation       615,000        
Accrued interest       23,862        
Notes payable       $ 772,970        
Fair value of common stock shares issued       1,942,456        
Fair value of common stock warrants issued       243,020        
Vested portion of common stock options issued       77,252        
Common stock options value outstanding       $ 19,015,073        
Estimated fair value       17,482,093        
Estimated fair value warrant issued       1,071,172        
Estimated vested options of fair value       461,808        
Goodwill       1,586,796        
Purchase price       19,015,073        
Assets acquired       $ 17,428,277